SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00525473

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Correlation of Genetic Polymorphism of Two Azathioprine Metabolizing Enzymes and Their Correlation to Clinical Adverse Effects

Azathioprine (AZA) has long been used in dermatology in treating autoimmune bullous dermatoses and generalized eczematous disorders as well as some photodermatoses. Its metabolic process inside human body and its side effects relies on genetic polymorphism of some enzymes such as thiopurine s-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase gene (ITPA). This study aims to analyze the relative contribution of TMPT and ITPA mutations to the development of toxicity induced by AZA treatment and to detect the correlation of the genetic polymorphism.

NCT00525473 Azathioprine Thiopurine Methyltransferase Inosine Triphosphate Pyrophosphatase Genetic Polymorphism

1 Interventions

Name: Azathioprine

Description: azathioprine usual dosage 100mg per day
Type: Drug


Primary Outcomes

Description: current treatment to nausea/vomiting adverse effects induced by azathioprine combined with pre-therapeutic genetic screening, especially polymorphism ITPA C94A, may reduce the possibility for developing hematopoietic toxicity and/or hepatotoxicity.

Measure: Genetic polymorphism tests before azathioprine therapy may reduce toxicity

Time: 2008.1.1

Time Perspective: Retrospective


There are 2 SNPs

SNPs


1 A719G

The aim of our study was to determine the relative contribution of, TMPT(A719G) and ITPA(C94A) mutations to the development of toxicity induced by AZA treatment in dermatology patients and to detect the correlation of these two genetic polymorphism. --- A719G ---


2 C94A

current treatment to nausea/vomiting adverse effects induced by azathioprine combined with pre-therapeutic genetic screening, especially polymorphism ITPA C94A, may reduce the possibility for developing hematopoietic toxicity and/or hepatotoxicity.. Inclusion Criteria: - Patients who have used or are using azathioprine in treating skin diseases will be asked about treatment effects and adverse events. --- C94A ---

The aim of our study was to determine the relative contribution of, TMPT(A719G) and ITPA(C94A) mutations to the development of toxicity induced by AZA treatment in dermatology patients and to detect the correlation of these two genetic polymorphism. --- A719G --- --- C94A ---



HPO Nodes